The recent discovery by our group that secretogranin III (Scg3) is a disease-selective angiogenic factor presents a unique opportunity to selectively target and alleviate ROP safely without affecting physiological angiogenesis and normal retinal development. This evidence concerns the gene SCG3 and retinopathy of prematurity.